Molecular Templates
MTEM
Market cap $3.08M

0.4672 USD

-0.1428

23.41%

At close Nov 15, 4:00 PM EST

After hours

0.4180

-0.0492

10.53%

1 day

-23.41%

5 days

31.24%

1 month

38.27%

3 months

-68.64%

6 months

-67.78%

Year to date

-87.44%

1 year

-91.05%

5 years

-99.57%

10 years

-99.90%

About: Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer. Its pipeline products are MT-6402, MT-8421 and MT-0169.

Employees: 62

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,704 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

33% more capital invested

Capital invested by funds: $3.25M [Q2] → $4.32M (+$1.07M) [Q3]

2.11% less ownership

Funds ownership: 43.0% [Q2] → 40.89% (-2.11%) [Q3]

18% less funds holding

Funds holding: 28 [Q2] → 23 (-5) [Q3]

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

71% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 7

100% less funds holding in top 10

Funds holding in top 10: 1 [Q2] → 0 (-1) [Q3]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for MTEM.

See Analyst Rankings

Financial journalist opinion

Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update

AUSTIN, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action, today reported financial results and business updates for the second quarter of 2024.

Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update

Molecular Templates, Inc. Provides Interim Update

AUSTIN, Texas, June 03, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage company focused on the discovery and development of targeted biologic therapeutics with unique mechanisms of action (engineered toxin bodies or “ETBs”) for cancer and immune-mediated disease, today provided an update on its clinical-stage programs.

Molecular Templates, Inc. Provides Interim Update

Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update

AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action, today reported financial results and business updates for the first quarter of 2024.

Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update

Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism

AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, today announced that MTEM will present a poster, “First-in-human, dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/refractory advanced solid tumors: Interim Data,” at the 2024 American Association for Cancer Research Annual Meeting taking place in San Diego, CA, and also announced monotherapy response activity in Head and Neck Cancer.

Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement

AUSTIN, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, announced today it has entered into a definitive amended and restated securities purchase agreement with certain healthcare investors that will provide $9.5 million in gross proceeds to MTEM through the closing of the second tranche of its previously announced July 2023 private placement and purchase agreement on amended terms. The financing is being led by existing investor BVF Partners L.P. and includes existing investors BB Biotech AG and Santé, and other leading institutional investors.

Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement

Top 5 Health Care Stocks Which Could Rescue Your Portfolio In March - Inspire Veterinary (NASDAQ:IVP), Fractyl Health (NASDAQ:GUTS)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks Which Could Rescue Your Portfolio In March - Inspire Veterinary (NASDAQ:IVP), Fractyl Health (NASDAQ:GUTS)

Molecular Templates, Inc. Provides Interim Update

Monotherapy activity with PD-L1-targeting MT-6402 in Head and Neck Cancer; Unique pharmacodynamic effects with CTLA-4 targeting MT-8421 in on-going phase I study Monotherapy activity with PD-L1-targeting MT-6402 in Head and Neck Cancer; Unique pharmacodynamic effects with CTLA-4 targeting MT-8421 in on-going phase I study

Molecular Templates, Inc. Provides Interim Update

Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

AUSTIN, Texas, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics with potent and differentiated mechanisms of action for cancer, announced participation in the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference.

Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

See News Rankings

Charts implemented using Lightweight Charts™